84 related articles for article (PubMed ID: 18487910)
1. [Combination therapy with molecular targeting drugs for head and neck cancer].
Fujii M
Gan To Kagaku Ryoho; 2008 May; 35(5):740-4. PubMed ID: 18487910
[TBL] [Abstract][Full Text] [Related]
2. [Comparative clinical studies for head and neck cancer in Japan].
Fujii M
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1502-8. PubMed ID: 12355935
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy with S-1 and carboplatin for head and neck cancers].
Watanabe A; Taniguchi M; Tsujie H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():155-9. PubMed ID: 16897993
[TBL] [Abstract][Full Text] [Related]
5. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
Moon C; Chae YK; Lee J
Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
7. Targeting important pathways in head and neck cancer: from the bench to the clinic.
Santos ES; Perez C; Donald CE; Raez LE
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1819-35. PubMed ID: 18983242
[TBL] [Abstract][Full Text] [Related]
8. Evolution of clinical trials in head and neck cancer.
Yang ES; Murphy BM; Chung CH; Netterville JL; Burkey BB; Gilbert J; Yarbrough WG; Sinard R; Cmelak AJ
Crit Rev Oncol Hematol; 2009 Jul; 71(1):29-42. PubMed ID: 18996026
[TBL] [Abstract][Full Text] [Related]
9. New chemoradiotherapy combinations in head and neck cancer.
Busto G; Corvò R; Ricci I; Sanguineti G; Benasso M
Expert Rev Anticancer Ther; 2001 Jun; 1(1):111-5. PubMed ID: 12113117
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
11. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
Ferrari D; Fiore J; Codecà C; Di Maria G; Bozzoni S; Bordin V; Caldiera S; Luciani A; Zonato S; Floriani I; Foa P
Anticancer Drugs; 2009 Mar; 20(3):185-90. PubMed ID: 19396017
[TBL] [Abstract][Full Text] [Related]
14. Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer.
Rengan R; Pfister DG; Lee NY; Kraus DH; Shah JP; Shaha AR; Ben-Porat LS; Zelefsky MJ
Am J Clin Oncol; 2008 Oct; 31(5):465-9. PubMed ID: 18838883
[TBL] [Abstract][Full Text] [Related]
15. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab.
Koutcher LD; Wolden S; Lee N
Am J Clin Oncol; 2009 Oct; 32(5):472-6. PubMed ID: 19487913
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients.
Nishimura G; Tsukuda M; Mikami Y; Matsuda H; Horiuchi C; Satake K; Taguchi T; Takahashi M; Kawakami M; Hanamura H; Watanabe M; Utsumi A
Auris Nasus Larynx; 2009 Oct; 36(5):547-54. PubMed ID: 19097833
[TBL] [Abstract][Full Text] [Related]
17. Functional outcomes in head and neck cancer.
List MA; Bilir SP
Semin Radiat Oncol; 2004 Apr; 14(2):178-89. PubMed ID: 15095263
[TBL] [Abstract][Full Text] [Related]
18. Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.
Lawenda BD; Arnold MG; Tokarz VA; Silverstein JR; Busse PM; McIntyre JF; Deschler DG; Baldini EH; Kachnic LA
Ear Nose Throat J; 2008 Nov; 87(11):634-43. PubMed ID: 19006065
[TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
20. Evolving strategies for combined-modality therapy for locally advanced head and neck cancer.
Posner M
Oncologist; 2007 Aug; 12(8):967-74. PubMed ID: 17766656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
